Cambium Bio（CMB）株式概要臨床段階の再生医療企業であるカンビウム・バイオ社は、眼科および組織修復用途の生物製剤の開発に注力している。 詳細CMB ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ 過去1年間で収益は19.1%減少しました 収益が 100 万ドル未満 ( A$669K )意味のある時価総額がありません ( A$12M )+1 さらなるリスクすべてのリスクチェックを見るCMB Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW461,592 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA461,592 investors already sharing narrativesYour Fair ValueAU$Current PriceAU$0.411.7k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-4m827k2016201920222025202620282031Revenue AU$668.8kEarnings AU$119.3kAdvancedSet Fair ValueView all narrativesCambium Bio Limited 競合他社AdAltaSymbol: ASX:1ADMarket cap: AU$9.6mImmuronSymbol: ASX:IMCMarket cap: AU$11.4mBCAL DiagnosticsSymbol: ASX:BDXMarket cap: AU$20.6mTissue RepairSymbol: ASX:TRPMarket cap: AU$5.1m価格と性能株価の高値、安値、推移の概要Cambium Bio過去の株価現在の株価AU$0.4152週高値AU$0.6052週安値AU$0.34ベータ-0.131ヶ月の変化0%3ヶ月変化3.80%1年変化13.89%3年間の変化n/a5年間の変化n/aIPOからの変化-68.46%最新ニュースお知らせ • Jul 22Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 1.008 million.Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 1.008 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,100,000 Price\Range: AUD 0.48 Transaction Features: Subsequent Direct ListingNew Risk • Apr 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Market cap is less than US$10m (AU$11.2m market cap, or US$7.99m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).New Risk • Mar 18New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 49% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Market cap is less than US$10m (AU$13.1m market cap, or US$9.32m).お知らせ • Mar 17Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 2.4 million.Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 2.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,363,637 Price\Range: AUD 0.55 Transaction Features: Subsequent Direct Listingお知らせ • Feb 11Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 10 million.Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 10 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 21,276,596 Price\Range: AUD 0.47 Transaction Features: Subsequent Direct Listingお知らせ • Jan 20Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 2.4 million.Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 2.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,363,637 Price\Range: AUD 0.55 Transaction Features: Subsequent Direct Listing最新情報をもっと見るRecent updatesお知らせ • Jul 22Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 1.008 million.Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 1.008 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,100,000 Price\Range: AUD 0.48 Transaction Features: Subsequent Direct ListingNew Risk • Apr 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Market cap is less than US$10m (AU$11.2m market cap, or US$7.99m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).New Risk • Mar 18New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 49% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Market cap is less than US$10m (AU$13.1m market cap, or US$9.32m).お知らせ • Mar 17Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 2.4 million.Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 2.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,363,637 Price\Range: AUD 0.55 Transaction Features: Subsequent Direct Listingお知らせ • Feb 11Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 10 million.Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 10 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 21,276,596 Price\Range: AUD 0.47 Transaction Features: Subsequent Direct Listingお知らせ • Jan 20Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 2.4 million.Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 2.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,363,637 Price\Range: AUD 0.55 Transaction Features: Subsequent Direct Listingお知らせ • Sep 15Cambium Bio Limited, Annual General Meeting, Oct 16, 2025Cambium Bio Limited, Annual General Meeting, Oct 16, 2025. Location: level 16, 101 miller street, north sydney, nsw 2060 Australiaお知らせ • Jul 30Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 2.17272 million.Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 2.17272 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,627,451 Price\Range: AUD 0.4637 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,828,266 Price\Range: AUD 0.4637 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 114,950 Price\Range: AUD 0.4637 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 114,948 Price\Range: AUD 0.4637 Transaction Features: Subsequent Direct Listingお知らせ • Mar 07Cambium Bio Limited Announces the Appointment of Li-Chien Chiu as Board of Director07 March 2025, Cambium Bio Limited announced the appointment of Mr. Li-Chien Chiu to its Board of Directors, effective immediately. Mr. Chiu is the Chairman of Hocheng Corporation. He brings extensive corporate leadership experience to Cambium Bio, having led Hocheng Corporation since 2003. Following Cambium Bio's recent capital raising, Mr. Chiu holds 800,357 shares, representing a 4.38% stake in the Company. Mr. Chiu brings over 35 years of corporate leadership experience across multiple industries. His career includes senior roles at Hostan Corporation (Vice President, 1998- 2003), Hocheng Corporation (Marketing Department Manager, 1996-1998), Sanquan Construction (Executive Director, 1993-1996), Hocheng Corporation North America Branch (Vice President, 1990-1993), and Hanyang Construction (Construction Site Director, 1988-1990). He holds a degree from the University of San Francisco, which he obtained in 1987. The appointment of Mr. Chiu further strengthens Cambium Bio's Board, which has recently been enhanced with the additions of Dr. ChiTai Chang in October 2024 and Clinical A/Prof Chandra Bala in November 2024. Together with existing Board members, this expanded leadership team possesses the diverse expertise necessary to guide Cambium Bio through its next phase of growth and clinical development.New Risk • Feb 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (AU$6.18m market cap, or US$3.92m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).お知らせ • Dec 05Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 2.950002 million.Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 2.950002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,349,385 Price\Range: AUD 0.4637 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,012,490 Price\Range: AUD 0.4637 Transaction Features: Subsequent Direct Listingお知らせ • Nov 22Cambium Bio Limited Announces Board ChangesCambium Bio Limited announced changes to its Board of Directors. Clinical A/Prof Chandra Bala, MBBS, PhD, will join Cambium's Board effective 22 November 2024. A world-renowned ophthalmologist, A/Prof Bala brings extensive expertise in cataract, cornea, and refractive surgery. His distinguished career spans academia, research, and clinical practice, with numerous publications in international peer- reviewed journals and significant involvement in Phase 2 to 4 ophthalmic clinical trials. As senior partner at PersonalEyes, a leading ophthalmic group operating 12 clinics across Australia, and in his role as a cornea surgeon at Macquarie University Hospital, A/Prof Bala demonstrates a commitment to excellence in patient care. His dedication to advancing ophthalmic medicine through translational research, teaching, and community service aligns perfectly with Cambium's mission to innovate in the field of regenerative medicine. Prof. Graham Vesey will retire from the Board of Directors effective as of 22 November 2024. The Board would like to thank Dr. Vesey for his contribution to the Company since its founding in 2007 and subsequent listing on the ASX in 2013.New Risk • Nov 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (18% average weekly change). Market cap is less than US$10m (AU$4.89m market cap, or US$3.22m).お知らせ • Oct 10Cambium Bio Limited Appoint Board of DirectorsCambium Bio Limited announced two key appointments to strengthen its scientific and leadership teams. Appointment of Dr. Louis Tong to Scientific Advisory Board. Dr. Louis Tong, a distinguished expert in ocular immunology and dry eye disease, has been appointed to Cambium Bio's Scientific Advisory Board. Dr. Tong is a Senior Consultant at the Singapore National Eye Centre, specializing in Corneal & External Eye Disease, and an Adjunct Associate Professor at the Yong Loo Lin School of Medicine, National University of Singapore. He is an internationally renowned clinician-scientist with over two decades of experience in ophthalmology, particularly in the areas of dry eye research and treatment development. He has authored more than 150 peer-reviewed publications and holds several patents in ophthalmic therapies. His wealth of expertise in clinical research will be instrumental in guiding Cambium Bio's ongoing development of novel dry eye disease therapeutics. Appointment of Dr. ChiTai Chang to Board of Directors. Dr. ChiTai Chang has been appointed to Cambium Bio's Board of Directors as a representative of Orient EuroPharma (Cyntec Co. Ltd.). Dr. Chang brings extensive experience in the pharmaceutical industry, with a strong background in strategic business development, commercialization of innovative products, and building partnerships in the healthcare sector. He has held senior leadership roles at multiple biotechnology firms where he successfully oversaw several drug development programs from early-stage research to regulatory approvals. Dr. Chang is currently the Chief Strategy Officer at Orient EuroPharma and holds a PhD in Chemistry from the University of Pittsburgh. Dr. Chang's proven track record in steering clinical programs to successful market entry will be invaluable as Cambium Bio progresses towards its goal of achieving FDA BLA approval for its lead candidate, Elate Ocular®, in dry eye disease. These appointments reflect Cambium Bio's ongoing commitment to enhancing its leadership capabilities and scientific acumen, ensuring the company remains at the forefront of ophthalmic innovation.お知らせ • Oct 03Cambium Bio Limited, Annual General Meeting, Nov 26, 2024Cambium Bio Limited, Annual General Meeting, Nov 26, 2024.Board Change • Apr 08No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元CMBAU BiotechsAU 市場7D13.9%16.6%-1.5%1Y13.9%-21.6%0.6%株主還元を見る業界別リターン: CMB過去 1 年間で-21.6 % の収益を上げたAustralian Biotechs業界を上回りました。リターン対市場: CMB過去 1 年間で0.6 % の収益を上げたAustralian市場を上回りました。価格変動Is CMB's price volatile compared to industry and market?CMB volatilityCMB Average Weekly Movement13.1%Biotechs Industry Average Movement9.8%Market Average Movement9.6%10% most volatile stocks in AU Market16.9%10% least volatile stocks in AU Market3.8%安定した株価: CMBの株価は、 Australian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: CMBの weekly volatility ( 13% ) は過去 1 年間安定していますが、依然としてAustralianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aKarolis Rosickaswww.cambium.bio臨床段階の再生医療企業であるカンビウム・バイオ社は、眼科および組織修復用途の生物製剤の開発に注力している。同社はドライアイ治療薬Elate Ocularを主力製品候補としている。また、変形性膝関節症やその他の組織修復を適応症とする幹細胞プラットフォームであるプロジェンザや、創傷治癒を適応症とするシジェナスも開発している。カンビウム・バイオ社の本社はオーストラリアのベラビスタにある。もっと見るCambium Bio Limited 基礎のまとめCambium Bio の収益と売上を時価総額と比較するとどうか。CMB 基礎統計学時価総額AU$12.07m収益（TTM）-AU$3.57m売上高(TTM)AU$668.79k18.0xP/Sレシオ-3.4xPER（株価収益率CMB は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CMB 損益計算書（TTM）収益AU$668.79k売上原価AU$211.45k売上総利益AU$457.34kその他の費用AU$4.03m収益-AU$3.57m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.12グロス・マージン68.38%純利益率-534.44%有利子負債／自己資本比率16.0%CMB の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/20 23:18終値2026/08/19 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cambium Bio Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関null nullLodge Partners Pty Ltd.
お知らせ • Jul 22Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 1.008 million.Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 1.008 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,100,000 Price\Range: AUD 0.48 Transaction Features: Subsequent Direct Listing
New Risk • Apr 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Market cap is less than US$10m (AU$11.2m market cap, or US$7.99m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).
New Risk • Mar 18New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 49% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Market cap is less than US$10m (AU$13.1m market cap, or US$9.32m).
お知らせ • Mar 17Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 2.4 million.Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 2.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,363,637 Price\Range: AUD 0.55 Transaction Features: Subsequent Direct Listing
お知らせ • Feb 11Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 10 million.Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 10 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 21,276,596 Price\Range: AUD 0.47 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 20Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 2.4 million.Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 2.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,363,637 Price\Range: AUD 0.55 Transaction Features: Subsequent Direct Listing
お知らせ • Jul 22Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 1.008 million.Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 1.008 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,100,000 Price\Range: AUD 0.48 Transaction Features: Subsequent Direct Listing
New Risk • Apr 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Market cap is less than US$10m (AU$11.2m market cap, or US$7.99m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).
New Risk • Mar 18New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 49% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (49% increase in shares outstanding). Market cap is less than US$10m (AU$13.1m market cap, or US$9.32m).
お知らせ • Mar 17Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 2.4 million.Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 2.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,363,637 Price\Range: AUD 0.55 Transaction Features: Subsequent Direct Listing
お知らせ • Feb 11Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 10 million.Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 10 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 21,276,596 Price\Range: AUD 0.47 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 20Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 2.4 million.Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 2.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,363,637 Price\Range: AUD 0.55 Transaction Features: Subsequent Direct Listing
お知らせ • Sep 15Cambium Bio Limited, Annual General Meeting, Oct 16, 2025Cambium Bio Limited, Annual General Meeting, Oct 16, 2025. Location: level 16, 101 miller street, north sydney, nsw 2060 Australia
お知らせ • Jul 30Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 2.17272 million.Cambium Bio Limited has completed a Follow-on Equity Offering in the amount of AUD 2.17272 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,627,451 Price\Range: AUD 0.4637 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,828,266 Price\Range: AUD 0.4637 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 114,950 Price\Range: AUD 0.4637 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 114,948 Price\Range: AUD 0.4637 Transaction Features: Subsequent Direct Listing
お知らせ • Mar 07Cambium Bio Limited Announces the Appointment of Li-Chien Chiu as Board of Director07 March 2025, Cambium Bio Limited announced the appointment of Mr. Li-Chien Chiu to its Board of Directors, effective immediately. Mr. Chiu is the Chairman of Hocheng Corporation. He brings extensive corporate leadership experience to Cambium Bio, having led Hocheng Corporation since 2003. Following Cambium Bio's recent capital raising, Mr. Chiu holds 800,357 shares, representing a 4.38% stake in the Company. Mr. Chiu brings over 35 years of corporate leadership experience across multiple industries. His career includes senior roles at Hostan Corporation (Vice President, 1998- 2003), Hocheng Corporation (Marketing Department Manager, 1996-1998), Sanquan Construction (Executive Director, 1993-1996), Hocheng Corporation North America Branch (Vice President, 1990-1993), and Hanyang Construction (Construction Site Director, 1988-1990). He holds a degree from the University of San Francisco, which he obtained in 1987. The appointment of Mr. Chiu further strengthens Cambium Bio's Board, which has recently been enhanced with the additions of Dr. ChiTai Chang in October 2024 and Clinical A/Prof Chandra Bala in November 2024. Together with existing Board members, this expanded leadership team possesses the diverse expertise necessary to guide Cambium Bio through its next phase of growth and clinical development.
New Risk • Feb 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (AU$6.18m market cap, or US$3.92m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).
お知らせ • Dec 05Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 2.950002 million.Cambium Bio Limited has filed a Follow-on Equity Offering in the amount of AUD 2.950002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,349,385 Price\Range: AUD 0.4637 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,012,490 Price\Range: AUD 0.4637 Transaction Features: Subsequent Direct Listing
お知らせ • Nov 22Cambium Bio Limited Announces Board ChangesCambium Bio Limited announced changes to its Board of Directors. Clinical A/Prof Chandra Bala, MBBS, PhD, will join Cambium's Board effective 22 November 2024. A world-renowned ophthalmologist, A/Prof Bala brings extensive expertise in cataract, cornea, and refractive surgery. His distinguished career spans academia, research, and clinical practice, with numerous publications in international peer- reviewed journals and significant involvement in Phase 2 to 4 ophthalmic clinical trials. As senior partner at PersonalEyes, a leading ophthalmic group operating 12 clinics across Australia, and in his role as a cornea surgeon at Macquarie University Hospital, A/Prof Bala demonstrates a commitment to excellence in patient care. His dedication to advancing ophthalmic medicine through translational research, teaching, and community service aligns perfectly with Cambium's mission to innovate in the field of regenerative medicine. Prof. Graham Vesey will retire from the Board of Directors effective as of 22 November 2024. The Board would like to thank Dr. Vesey for his contribution to the Company since its founding in 2007 and subsequent listing on the ASX in 2013.
New Risk • Nov 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (18% average weekly change). Market cap is less than US$10m (AU$4.89m market cap, or US$3.22m).
お知らせ • Oct 10Cambium Bio Limited Appoint Board of DirectorsCambium Bio Limited announced two key appointments to strengthen its scientific and leadership teams. Appointment of Dr. Louis Tong to Scientific Advisory Board. Dr. Louis Tong, a distinguished expert in ocular immunology and dry eye disease, has been appointed to Cambium Bio's Scientific Advisory Board. Dr. Tong is a Senior Consultant at the Singapore National Eye Centre, specializing in Corneal & External Eye Disease, and an Adjunct Associate Professor at the Yong Loo Lin School of Medicine, National University of Singapore. He is an internationally renowned clinician-scientist with over two decades of experience in ophthalmology, particularly in the areas of dry eye research and treatment development. He has authored more than 150 peer-reviewed publications and holds several patents in ophthalmic therapies. His wealth of expertise in clinical research will be instrumental in guiding Cambium Bio's ongoing development of novel dry eye disease therapeutics. Appointment of Dr. ChiTai Chang to Board of Directors. Dr. ChiTai Chang has been appointed to Cambium Bio's Board of Directors as a representative of Orient EuroPharma (Cyntec Co. Ltd.). Dr. Chang brings extensive experience in the pharmaceutical industry, with a strong background in strategic business development, commercialization of innovative products, and building partnerships in the healthcare sector. He has held senior leadership roles at multiple biotechnology firms where he successfully oversaw several drug development programs from early-stage research to regulatory approvals. Dr. Chang is currently the Chief Strategy Officer at Orient EuroPharma and holds a PhD in Chemistry from the University of Pittsburgh. Dr. Chang's proven track record in steering clinical programs to successful market entry will be invaluable as Cambium Bio progresses towards its goal of achieving FDA BLA approval for its lead candidate, Elate Ocular®, in dry eye disease. These appointments reflect Cambium Bio's ongoing commitment to enhancing its leadership capabilities and scientific acumen, ensuring the company remains at the forefront of ophthalmic innovation.
お知らせ • Oct 03Cambium Bio Limited, Annual General Meeting, Nov 26, 2024Cambium Bio Limited, Annual General Meeting, Nov 26, 2024.
Board Change • Apr 08No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
